PremiumThe FlyKorro Bio reports Q1 EPS ($2.49), consensus ($2.62) Korro Bio Announces Strategic Workforce Reduction Plan Korro Bio initiated with an Overweight at Cantor Fitzgerald PremiumCompany AnnouncementsKorro Bio Reports 2024 Financial Results and Progress Korro Bio price target lowered to $95 from $105 at RBC Capital Korro Bio’s Promising Growth: Buy Rating Backed by Positive KRRO-110 Trial Progress and Market Opportunities PremiumThe FlyKorro Bio announces initiation of dosing in its REWRITE study on KRRO-110 Korro initiated with Outperform into 2025 catalysts at Oppenheimer Korro Bio initiated with an Outperform at Oppenheimer 
